Clinical trials have demonstrated that the combination of KRAS G12C inhibitors with EGFR inhibitors results in longer progression-free survival (PFS: the time period during and after treatment when a patient lives without the cancer worsening) and improved overall survival in patients with KRAS G12C-mutated colorectal cancer compared to standard treatments [98]. This evidence concerns the gene KRAS and colorectal cancer.